雷公藤多苷联合达格列净治疗糖尿病肾病的疗效分析

Efficacy analysis of Tripterygium Polyglycosides combined with Dapagliflozin in treatment of diabetic kidney disease

目的探讨雷公藤多苷联合达格列净治疗糖尿病肾病的临床疗效。方法将2020年1月—2021年6月本院确诊的2型糖尿病肾病患者120例,按照随机数表法分为对照组及观察组,每组患者60例。两组均进行常规治疗,在此基础上对照组给予达格列净治疗,观察组给予雷公藤多苷联合达格列净治疗。比较两组的临床治疗效果,包括治疗前后的肾功能指标、代谢指标,同时记录治疗过程中出现的不良反应。结果治疗效果方面,观察组的血肌酐、24 h尿蛋白定量均较对照组下降,血白蛋白较对照组升高,肾功能指标差异具有统计学意义(P<0.05);两组的空腹血糖、糖化血红蛋白、血尿酸水平均较治疗前明显下降,但组间无统计学差异(P>0.05)。不良反应方面,观察组和对照组治疗后低血糖、肝功损害等相关不良反应发生率分别为8.33%和6.67%,但差异无统计学意义(P>0.05)。结论在糖尿病肾病的治疗中,雷公藤多苷联合达格列净可有效降低患者血肌酐和尿蛋白水平,升高人血白蛋白,进而改善患者的肾脏预后,同时不良反应无明显增加,整体临床效果较理想。

Objective To investigate the clinical effect of Tripterygium Polyglycosides combined with Dapaglifozin in the treatment of diabetic kidney disease.Methods A total of 120 patients with diabetic kidney disease admitted from January 2020 to June 2021 were divided into control group and observation group by random number table method,with 60 cases in each group.Both groups received routine treatment.On this basis,the control group was treated with Dapagliflozin,and the observation group was treated with Tripterygium Polyglycosides combined with Dapagliflozin.The clinical therapeutic effects of the two groups were compared,including renal function indexes and metabolic indexes before and after treatment,and the adverse reactions during the treatment were recorded at the same time.Results In terms of therapeutic effect,the decrease of serum creatinine and 24-hour urinary protein quantification in the observation group was significantly higher than that in the control group,and the difference was statistically significant(P<0.05).The increase of serum albumin in the observation group was higher than that in the control group.The levels of fasting blood glucose,glycosylated hemoglobin and blood uric acid level in the two groups were significantly lower than those before treatment,but there was no statistical difference between the two groups(P>0.05).In terms of adverse reactions,the incidence of adverse reactions in the observation group and the control group after treatment was 8.33%and 6.67%,respectively,and the difference was not statistically significant(P>0.05).Conclusion In the treatment of diabetic kidney disease,Tripterygium Polyglycosides combined with Dapagliflozin can effectively reduce the levels of serum creatinine and urinary protein,increase serum albumin,and improve the renal prognosis of patients,without significant increase in adverse reactions.The overall clinical effect is ideal.